v3.25.4
Mergers, Acquisition of Opus Genetics, Purchase Price (Details)
$ / shares in Units, $ in Thousands
Oct. 22, 2024
USD ($)
$ / shares
shares
Series A Preferred Stock [Member]  
Acquisition of Opus Genetics [Abstract]  
Common stock, conversion basis (in shares) 1
Common Stock [Member]  
Acquisition of Opus Genetics [Abstract]  
Common stock, conversion basis (in shares) 1,000
Opus Genetics, Inc. [Member]  
Acquisition of Opus Genetics [Abstract]  
Purchase price | $ $ 25,808
Opus Genetics, Inc. [Member] | Series A Preferred Stock [Member]  
Acquisition of Opus Genetics [Abstract]  
Number of shares of the combined organization owned by the company's pre-acquisition Private Opus stockholders (in shares) 14,145.374
Multiplied by the fair value per share (in dollars per share) | $ / shares $ 1.3321 [1]
Fair value of stock issued to affect the acquisition | $ $ 18,843
Opus Genetics, Inc. [Member] | Common Stock [Member]  
Acquisition of Opus Genetics [Abstract]  
Number of shares of the combined organization owned by the company's pre-acquisition Private Opus stockholders (in shares) 5,237,063
Multiplied by the fair value per share (in dollars per share) | $ / shares $ 1.33 [2]
Fair value of stock issued to affect the acquisition | $ $ 6,965
[1] Based on the fair market valuation of the Series A preferred stock that considered the reported sale price of the Company’s common stock on the Nasdaq Capital Market on October 22, 2024 on an as converted basis (1,000 shares of common stock for 1 share of preferred stock), the closing date of the Opus Acquisition, as well as the underlying dividend provisions on a discounted cash flow basis.
[2] Based on the last reported sale price of the Company’s common stock on the Nasdaq Capital Market on October 22, 2024, the closing date of the Opus Acquisition.